Tasmina Hydery of Cencora Talks Collaborative Approach to Boost Uptake of HUMIRA Biosimilars | Asembia 2024
Tasmina Hydery, Pharm.D., MBA, associate director, digital solutions, Cencora, spoke with MHE editors about the slow uptake of HUMIRA biosimilars despite there being 10 approved options on the market.
Tasmina Hydery, Pharm.D., MBA, spoke with MHE editors about the slow uptake of HUMIRA biosimilars despite there being 10 approved options on the market.
Hydery stressed the need for a collaborative effort among various stakeholders including manufacturers, providers, distributors and regulators to increase adoption. She also mentioned recent positive developments such as CVS Health's decision to remove HUMIRA from its international formularies and the VA's preference for an adalimumab biosimilar on their national formulary.
She suggests that time and energy investment are crucial for change to occur, as contracts between stakeholders are implemented post-approval. She also noted the importance of pricing in contracting decisions, with net price being particularly significant.
Additionally, Hydery discussed the value of pre-approval planning for manufacturers.
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
